Serum complement C3: a determinant of cardiometabolic risk, additive to the metabolic syndrome, in middle-aged population.

[1]  G. Can,et al.  The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. , 2010, International journal of cardiology.

[2]  G. Can,et al.  Serum apolipoprotein C‐III in high‐density lipoprotein: a key diabetogenic risk factor in Turks , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[3]  G. Can,et al.  Impaired protection against diabetes and coronary heart disease by high-density lipoproteins in Turks. , 2009, Metabolism: clinical and experimental.

[4]  K. Cianflone,et al.  Acylation stimulating protein but not complement C3 associates with metabolic syndrome components in Chinese children and adolescents. , 2008, European journal of endocrinology.

[5]  G. Can,et al.  Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. , 2008, Metabolism: clinical and experimental.

[6]  I. Borecki,et al.  Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster? , 2007, Nutrition & metabolism.

[7]  M. Zoli,et al.  Serum C3 Is a Stronger Inflammatory Marker of Insulin Resistance Than C-Reactive Protein, Leukocyte Count, and Erythrocyte Sedimentation Rate , 2007, Diabetes Care.

[8]  G. Can,et al.  Prospective epidemiologic evidence of a "protective" effect of smoking on metabolic syndrome and diabetes among Turkish women--without associated overall health benefit. , 2007, Atherosclerosis.

[9]  B. Hedblad,et al.  Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[10]  H. Haario,et al.  Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. , 2007, The American journal of cardiology.

[11]  A. Carter,et al.  Ethnic differences in cardiovascular risk factors in healthy Caucasian and South Asian individuals with the metabolic syndrome , 2007, Journal of thrombosis and haemostasis : JTH.

[12]  G. Can,et al.  Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. , 2007, Atherosclerosis.

[13]  K. Cianflone,et al.  Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes , 2006, International Journal of Obesity.

[14]  A. Carter,et al.  Complement C3 and C-reactive protein levels in patients with stable coronary artery disease , 2005, Thrombosis and Haemostasis.

[15]  K. Eriksson,et al.  Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. , 2005, Diabetes.

[16]  G. Can,et al.  Cross-sectional study of complement C3 as a coronary risk factor among men and women. , 2005, Clinical science.

[17]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[18]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[19]  P. Kovanen,et al.  Role of complement activation in atherosclerosis , 2003, Current opinion in lipidology.

[20]  K. Cianflone,et al.  Critical review of acylation-stimulating protein physiology in humans and rodents. , 2003, Biochimica et biophysica acta.

[21]  A. Onat,et al.  Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation. , 2002, Atherosclerosis.

[22]  John D Lambris,et al.  Phylogenetic aspects of the complement system. , 2001, Developmental and comparative immunology.

[23]  A. Onat.  Risk factors and cardiovascular disease in Turkey. , 2001, Atherosclerosis.

[24]  C. Martignani,et al.  Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. , 2000, European heart journal.

[25]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[26]  P. Puddu,et al.  Association of serum C3 levels with the risk of myocardial infarction. , 1995, The American journal of medicine.

[27]  K. Cianflone,et al.  The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. , 1993, The Journal of clinical investigation.

[28]  K. Cianflone,et al.  Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. , 1993, Metabolism: clinical and experimental.

[29]  H. Blackburn,et al.  Cardiovascular survey methods. , 1969, Monograph series. World Health Organization.

[30]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[31]  A. Sniderman,et al.  The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. , 2007, Atherosclerosis.